Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telbivudine/Torcitabine Idenix/Novartis.

R Anthony Vere Hodge1

  • 1Vere Hodge AntiVirals Ltd, Old Denshott, Leigh, Reigate, Surrey, RH2 8RD, UK. averehodge@aol.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 27, 2004
PubMed
Summary

Idenix and Novartis are developing novel nucleoside analogs, telbivudine and valtorcitabine, for treating hepatitis B virus infection. Clinical trials are progressing to evaluate the efficacy of these antiviral agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA.

Antiviral chemistry & chemotherapy·2018
Same author

Highlights of the 30th International Conference on Antiviral Research.

Antiviral research·2017
Same author

Meeting report: 29th International Conference on Antiviral Research in La Jolla, CA, USA.

Antiviral research·2016
Same author

Meeting report: 28th International Conference on Antiviral Research in Rome, Italy.

Antiviral research·2015
Same author

Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA.

Antiviral research·2014
Same author

Meeting report: 26th International Conference on Antiviral Research.

Antiviral research·2013

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis B virus (HBV) infection poses a significant global health challenge.
  • Nucleoside analogs are a key therapeutic strategy for managing chronic HBV.
  • Developing novel antiviral agents with improved efficacy and safety profiles is crucial.

Purpose of the Study:

  • To investigate the development of two beta-L-deoxynucleosides, telbivudine and valtorcitabine, for potential hepatitis B virus treatment.
  • To report on the clinical trial progress of these investigational drugs.

Main Methods:

  • Telbivudine and valtorcitabine (a prodrug of torcitabine) are beta-L-deoxynucleosides.
  • Clinical trials, including Phase III for telbivudine and Phase I/II for valtorcitabine, were conducted.

Main Results:

  • Phase III trials for telbivudine were initiated by August 2002.
  • Phase I/II trials for valtorcitabine were ongoing as of November 2003.

Conclusions:

  • Telbivudine and valtorcitabine represent promising therapeutic candidates for hepatitis B virus infection.
  • Ongoing clinical development indicates continued research into these nucleoside analogs for antiviral therapy.

Related Experiment Videos